KERNAL
Live / Allowed — Third extension granted (statement of use) (as of 28 Apr 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 18 Jul 2022 filing date already counts against anyone who files later.
Record
- Serial number
- 97507484
- Mark type
- Word mark
- Filed
- 18 Jul 2022
- Published for opposition
- 03 Sept 2024
- Attorney of record
- Brandon P. Leahy
Goods and services
- Class 001 — Chemicals: Chemicals for use in biotechnological manufacturing processes; Chemicals for use in biotechnological product development; Biochemicals for use in biotechnological manufacturing processes and product development, namely, protein-encoding nucleic acids and polypeptide-encoding nucleic acids related to treating cancers, auto-immune diseases, cardio metabolic diseases, infectious diseases, inflammatory diseases, and metabolic diseases; nucleotides for scientific and research use; biochemical reagents commonly known as probes, for detecting and analyzing molecules in protein or nucleotide arrays; protein arrays and nucleotide arrays for scientific and medical research; nucleic acid for laboratory use; chemical solutions and preparations consisting of pre-mixed reactants and reagents for scientific and research use in connection with amplification, analysis or labeling of nucleic acid; nucleic acid isolation and purification kit consisting primarily of reagents and magnetic beads for scientific research purposes; nucleic acid sequences for scientific purposes; polypeptide encoding nucleic acids for laboratory use
- Class 005 — Pharmaceuticals: Medical, biological, and pharmaceutical preparations for treating cancers, auto-immune diseases, cardio metabolic diseases, infectious diseases, inflammatory diseases, and metabolic diseases; RNA-based therapeutics and therapeutic agents for in vivo, ex vivo, or in situ treatment of cancers, auto-immune diseases, cardio metabolic diseases, infectious diseases, inflammatory diseases, and metabolic diseases; medical, biological and pharmaceutical preparations containing lipid nanoparticles for the prevention and treatment of cancers, auto-immune diseases, cardio metabolic diseases, infectious diseases, inflammatory diseases, and metabolic diseases; RNA-based therapeutics and therapeutic agents for in vitro preparation and in vivo, ex vivo, or on vivo delivery to cell sites; nucleic acid sequences and chemical reagents for medical and veterinary purposes
Owner
- Kernal Biologics, Cambridge, MA, US
- Kernal Biologics, Cambridge, MA, US
Prosecution history
- 28 Apr 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 28 Apr 2026 — SOU EXTENSION 3 GRANTED
- 27 Apr 2026 — SOU EXTENSION 3 FILED
- 27 Apr 2026 — SOU TEAS EXTENSION RECEIVED
- 29 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 28 Oct 2025 — SOU EXTENSION 2 GRANTED
- 28 Oct 2025 — SOU EXTENSION 2 FILED
- 28 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 22 Apr 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 21 Apr 2025 — SOU EXTENSION 1 GRANTED
- 21 Apr 2025 — SOU EXTENSION 1 FILED
- 21 Apr 2025 — SOU TEAS EXTENSION RECEIVED
- 29 Oct 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 03 Sept 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 03 Sept 2024 — PUBLISHED FOR OPPOSITION